187 related articles for article (PubMed ID: 29468896)
1. Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
Tanton D; Duh MS; Lafeuille MH; Lefebvre P; Pilon D; Zhdanava M; Emond B; Inman D; Bailey RA
Curr Med Res Opin; 2018 Jun; 34(6):1099-1115. PubMed ID: 29468896
[TBL] [Abstract][Full Text] [Related]
2. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
[TBL] [Abstract][Full Text] [Related]
3. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
4. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
5. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
[TBL] [Abstract][Full Text] [Related]
6. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
[TBL] [Abstract][Full Text] [Related]
7. Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA
Johnson JF; Parsa R; Bailey RA
Clin Ther; 2017 Jun; 39(6):1123-1131. PubMed ID: 28495028
[TBL] [Abstract][Full Text] [Related]
8. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
9. Real world clinical outcomes and patient characteristics for canagliflozin treated patients in a specialty diabetes clinic.
Johnson JF; Parsa R; Bailey R
Curr Med Res Opin; 2017 Jan; 33(1):77-84. PubMed ID: 27646315
[TBL] [Abstract][Full Text] [Related]
10. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
Merton K; Davies MJ; Vijapurkar U; Inman D; Meininger G
Curr Med Res Opin; 2018 Feb; 34(2):313-318. PubMed ID: 29022746
[TBL] [Abstract][Full Text] [Related]
11. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Duh MS; Lefebvre P
J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
[TBL] [Abstract][Full Text] [Related]
12. CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Culham MD; Rose JB; Rapattoni W; Bajaj HS
Diabetes Obes Metab; 2019 Mar; 21(3):691-699. PubMed ID: 30393961
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA
Ali AM; Martinez R; Al-Jobori H; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
Diabetes Care; 2020 Jun; 43(6):1234-1241. PubMed ID: 32220916
[TBL] [Abstract][Full Text] [Related]
14. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
[TBL] [Abstract][Full Text] [Related]
16. CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Rose JB; Sorabji D; Bajaj HS
Can J Diabetes; 2019 Oct; 43(7):464-471. PubMed ID: 31133438
[TBL] [Abstract][Full Text] [Related]
17. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Bailey RA; Vijapurkar U; Meininger G; Rupnow MF; Blonde L
Clin Ther; 2015 May; 37(5):1045-54. PubMed ID: 25795432
[TBL] [Abstract][Full Text] [Related]
18. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
Cefalu WT; Stenlöf K; Leiter LA; Wilding JP; Blonde L; Polidori D; Xie J; Sullivan D; Usiskin K; Canovatchel W; Meininger G
Diabetologia; 2015 Jun; 58(6):1183-7. PubMed ID: 25813214
[TBL] [Abstract][Full Text] [Related]
19. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
